<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Klompas, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julio A Ramirez, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Community-acquired pneumonia (CAP) is one of the most commonly diagnosed illnesses worldwide. The clinical presentation of CAP varies, ranging from mild disease characterized by limited shortness of breath and productive cough to severe disease characterized by fever, respiratory distress, and sepsis. Because of the wide spectrum of associated clinical features, CAP is a part of the differential diagnosis of most acute respiratory illnesses.</p><p>In patients with a clinically compatible syndrome, the demonstration of an infiltrate on chest imaging is generally sufficient to establish an initial working diagnosis and start empiric therapy. However, this combination of findings is ultimately nonspecific and is shared among many cardiopulmonary disorders. Thus, it is important to remain attentive to the possibility of an alternate diagnosis as a patient's course evolves.</p><p>The clinical manifestations, diagnosis, and microbiologic evaluation of CAP in immunocompetent adults are reviewed here. An general overview of CAP in adults is provided separately (see  <a class="medical medical_review" href="/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults"</a>). Links to detailed topics on the epidemiology, management, and prognosis of CAP are provided within the overview topic and at relevant places within the text below. </p><p class="headingAnchor" id="H3261777362"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>The diagnosis of CAP generally requires the demonstration of an opacity on chest imaging in a patient with a clinically compatible syndrome (eg, fever, dyspnea, cough, and sputum production) [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with suspected CAP, we obtain posteroanterior and lateral chest radiographs. Radiographic findings consistent with the diagnosis of CAP include lobar consolidations  (<a class="graphic graphic_diagnosticimage graphicRef65658 graphicRef64692" href="/d/graphic/65658.html" rel="external">image 1A-B</a>), interstitial infiltrates  (<a class="graphic graphic_diagnosticimage graphicRef116892 graphicRef86363 graphicRef62313" href="/d/graphic/116892.html" rel="external">image 2A-C</a>), and/or cavitations  (<a class="graphic graphic_diagnosticimage graphicRef53664" href="/d/graphic/53664.html" rel="external">image 3</a>). Although certain radiographic features suggest specific causes of pneumonia (eg, lobar consolidations suggest infection with typical bacterial pathogens), radiographic appearance alone cannot reliably differentiate among etiologies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In selected cases, it is reasonable to make a clinical diagnosis without chest imaging in otherwise healthy patients with highly compatible syndromes (eg, acute onset, fever, cough, and signs of consolidation on physical examination) and lack of concern for other causes. However, clinical features alone have limited diagnostic accuracy, thus, we typically reserve this option for circumstances in which chest radiography cannot be easily obtained and the patient can be closely followed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When CAP is suspected based on clinical features despite a negative chest radiograph, we obtain computed tomography (CT) of the chest in selected patients. These patients include immunocompromised patients, who may not mount strong inflammatory responses and thus have negative chest radiographs, as well as patients with known exposures to epidemic pathogens that cause pneumonia (eg, severe acute respiratory syndrome coronavirus 2, <em>Legionella </em>spp). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtaining a CT scan is also reasonable when CAP is suspected but the clinical presentation is atypical or the patient has possible alternative explanations for their syndrome (eg, chronic obstructive pulmonary disease exacerbation, pulmonary edema, atelectasis, etc). In such cases, CT scanning can help confirm or exclude the diagnosis of pneumonia [<a href="#rid2">2</a>]. Because there is no direct evidence to suggest that CT scanning improves outcomes for most patients and cost is high, we do not routinely obtain CT scans when evaluating patients for CAP. (See <a class="local">'Chest imaging findings'</a> below.)</p><p></p><p>All patients with possible CAP should be tested for coronavirus disease 2019 during the pandemic. Microbiologic testing is otherwise generally reserved for hospitalized patients and for selected outpatients in which test results could change management (eg, immunocompromised patients, patients who fail to improve with empiric therapy, during outbreaks with certain organisms such as <em>Legionella </em>spp,<em> </em>or following exposures to specific pathogens such as influenza virus)  (<a class="graphic graphic_table graphicRef118966" href="/d/graphic/118966.html" rel="external">table 1</a>). However, the accuracy, availability, and affordability of rapid microbiologic diagnostics tests is growing, and we expect that indications for testing will broaden soon [<a href="#rid3">3</a>]. (See <a class="local">'Microbiologic testing'</a> below.)</p><p>In all cases, the initial diagnosis of CAP should be considered a working diagnosis. A substantial portion of patients initially diagnosed with CAP are ultimately found to have alternate diagnoses [<a href="#rid4">4</a>], therefore, findings that further support or refute the initial diagnoses should continue to be sought as the patient’s course progresses.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL EVALUATION</span></p><p class="headingAnchor" id="H306508906"><span class="h2">History and physical</span><span class="headingEndMark"> — </span>The history and physical examination should be directed at recognizing the clinical syndrome of CAP, evaluating its severity, assessing for complications, identifying important exposures that may indicate the cause of infection, and assessing for comorbidities that may contribute to the patient’s symptoms. </p><p>Classically, CAP is characterized by acute onset fever, cough (with or without sputum production), and shortness of breath [<a href="#rid5">5-7</a>]. In some cases, pleuritic chest pain may also be present. Less common symptoms include gastrointestinal complaints (eg, nausea, vomiting, diarrhea, abdominal pain), loss of appetite, and mental status changes. In patients with advanced age or impaired immune systems, presenting symptoms can be subtle. For example, fever may be absent in older patients and mental status changes may be the sole presenting symptom [<a href="#rid8">8,9</a>]. Tachycardia, tachypnea, hypoxemia, or increased work of breathing may be present on physical examination. Crackles (rales) and rhonchi may be heard on chest auscultation, along with other signs of consolidation (eg, tactile fremitus, egophony, dullness to percussion). As infection progresses, the dominant clinical picture may be of sepsis and/or respiratory distress. </p><p>While the clinical features described above support the diagnosis of pneumonia, no combination of symptoms and signs has been found to accurately predict the presence or absence of pneumonia [<a href="#rid6">6,7,10</a>]. As an example, the sensitivity of the combination of fever, cough, tachycardia, and crackles was less than 50 percent when chest radiograph was used as a reference standard in one retrospective review [<a href="#rid6">6</a>]. In another study evaluating &gt;28,000 adults presenting to primary care with an acute cough attributed to a lower respiratory tract infection, independent predictors of radiographic-confirmed pneumonia included fever, tachycardia, crackles on chest auscultation, and oxygen saturation &lt;95 percent [<a href="#rid7">7</a>]. However, the positive predictive value (PPV) of all four variables combined was estimated to be only 67 percent. Concordantly, studies comparing clinical judgement with chest radiography for the diagnosis of pneumonia have similar findings [<a href="#rid6">6,11</a>]. One cohort study of &gt;2800 adults with acute cough estimates the PPV of clinical judgement at 57 percent [<a href="#rid11">11</a>]. </p><p>Similarly, there are no signs or symptoms that reliably distinguish among the many infectious causes of pneumonia (eg, viral versus bacterial or between different bacterial causes) [<a href="#rid12">12</a>]. However, the presence of certain features may raise the index of suspicion for particular pathogens  (<a class="graphic graphic_table graphicRef52808" href="/d/graphic/52808.html" rel="external">table 2</a>). This concept is particularly important during outbreaks, family clusters, and other known/potential exposures, where knowledge of a particular exposure may change the need for testing, alter empiric therapy selection, require quarantine, or other public health action. (See <a class="local">'Important pathogens'</a> below.)</p><p class="headingAnchor" id="H1690098113"><span class="h2">Laboratory evaluation</span></p><p class="headingAnchor" id="H2812817410"><span class="h3">Routine blood tests</span><span class="headingEndMark"> — </span>We generally obtain a complete blood count with differential and a basic metabolic panel for most patients with known or suspected CAP who are being hospitalized or who may require hospitalization based on their age, comorbidities, vital signs, or clinical appearance. Results help corroborate the diagnosis of CAP and inform the need for hospitalization and level of care (ie, need for intensive care). (See  <a class="medical medical_review" href="/d/html/7022.html" rel="external">"Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytosis is the most common blood test abnormality with a leftward shift. Leukopenia (&lt;4000 cells per mm<sup>3</sup>) is less common but generally connotes poorer prognosis [<a href="#rid13">13,14</a>]. Similarly, thrombocytopenia (platelet count &lt;100,000 cells per mm<sup>3</sup>) is an uncommon finding but one that suggests poorer outcome. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New elevations in creatinine and blood urea nitrogen also connote poor prognosis and often indicate need for hospitalization. These values along with abnormal liver function tests can be also be signs of sepsis, which mandates immediate additional evaluation and care. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p></p><p class="headingAnchor" id="H214396184"><span class="h3">Serum biomarkers</span><span class="headingEndMark"> — </span>While there is much interest in using C-reactive protein (CRP) and procalcitonin to aid in the diagnosis of pneumonia and to help distinguish bacterial from viral causes of CAP [<a href="#rid15">15-24</a>], we do not find that these tests reliably add value to the initial clinical and radiographic evaluation [<a href="#rid1">1,25,26</a>]. The reported sensitivity and specificity of CRP for pneumonia both range from approximately 40 to 90 percent and vary substantially with the cutoff value used [<a href="#rid15">15-19</a>]. Similarly, the reported sensitivity for procalcitonin ranges widely from 38 to 91 percent [<a href="#rid1">1</a>]. A randomized trial of procalcitonin measurement in addition to clinical evaluation versus clinical evaluation alone for patients presenting to the emergency department with possible lower respiratory tract infection in whom clinicians were uncertain whether antibiotics were needed or not did not show any difference in antibiotic utilization or patient outcomes [<a href="#rid25">25</a>].</p><p>However, procalcitonin, in conjunction with clinical judgement, can help guide the decision to discontinue antibiotic treatment. Detailed discussion about procalcitonin in respiratory tract infections is provided separately and focuses on the utility of the assay in guiding antibiotic de-escalation in patients with established diagnoses of CAP. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Community-acquired pneumonia in hospitalized patients'</a>.)</p><p class="headingAnchor" id="H557987629"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>CAP is a common working diagnosis and is on the differential diagnosis of patients presenting with respiratory tract infections, patients with cough and abnormal chest imaging, and patients with sepsis. Because CAP is common and its symptoms overlap with many other cardiopulmonary disorders, it is frequently overdiagnosed [<a href="#rid4">4</a>]. In one cohort study, approximately 17 percent of patients hospitalized with CAP were ultimately found to have a different diagnosis. The most common alternate diagnoses included heart failure, malignancy, and pulmonary infarct or fibrosis [<a href="#rid4">4</a>]. </p><p>Other respiratory tract infections that present similarly to CAP include, but are not limited, to influenza, coronavirus disease 2019 (COVID-19), acute bronchitis, chronic obstructive pulmonary disease exacerbations, and other respiratory tract infections. Generally, signs of consolidation on chest auscultation and the presence of an opacity on chest imaging distinguish CAP from the latter two disorders. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute bronchitis</strong> – Acute bronchitis is an infection that primarily involves the large airways (bronchi) but not the alveoli or pulmonary parenchyma. Prolonged cough, typically following an upper respiratory tract infection, is the most common symptom of acute bronchitis. In contrast to pneumonia, acute bronchitis is less likely to present with abnormal vital signs (pulse &gt;100/minute, respiratory rate &gt;24 breaths/minute, temperature &gt;38°C [100.4°F], or oxygen saturation &lt;95 percent)  (<a class="graphic graphic_figure graphicRef135143" href="/d/graphic/135143.html" rel="external">figure 1</a>). Mental status changes and/or other signs of systemic infection are typically absent. Signs of consolidation (rales, egophony, or tactile fremitus) should be absent on chest auscultation. (See  <a class="medical medical_review" href="/d/html/6870.html" rel="external">"Acute bronchitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – Influenza is characterized by acute onset fever and cough, often accompanied by pronounced systemic symptoms including chills, rigors, myalgias, and/or arthralgias. Pneumonia complicates a minority of cases and may be primary (caused by influenza virus itself) or secondary, caused by bacterial respiratory pathogens (most often streptococci or <em>Staphylococcus aureus</em>). (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper respiratory tract infection (URI)</strong> – URIs are commonly characterized by fever and cough, but in contrast to pneumonia lack signs of consolidation on chest auscultation. While the presence of rhinorrhea and pharyngitis favor the diagnosis URI over pneumonia, URIs sometimes precede or co-occur with CAP [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6865.html" rel="external">"The common cold in adults: Diagnosis and clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronavirus disease 2019 </strong>– The range of presenting symptoms for COVID-19 is wide, ranging from asymptomatic infection to CAP with profound acute respiratory failure. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>.)</p><p></p><p>Exacerbations of chronic pulmonary diseases are frequently triggered by viral or bacterial infection or colonization of the respiratory tract mucosa. In most cases, infection does not extend beyond the mucosa, however, pneumonia can complicate these disorders. Higher fever, adventitious breath sounds on chest auscultation (eg, focal rales/crackles or rhonchi), and impaired oxygenation suggest pneumonia and generally indicate need for chest imaging. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute exacerbations of chronic obstructive pulmonary disease</strong> (AECOPD) – AECOPD is defined as an acute increase in COPD symptoms that go beyond day-to-day variation, typically characterized by increases in dyspnea, sputum volume/viscosity, and/or sputum purulence. (See  <a class="medical medical_review" href="/d/html/122144.html" rel="external">"COPD exacerbations: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute asthma exacerbations</strong> – Cough (often worse at night), wheezing, and shortness of breath are characteristics symptoms of asthma exacerbations. In contrast to AECOPD, infectious triggers are less common. (See  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute exacerbations of bronchiectasis </strong>–<strong> </strong>Worsening cough, sputum production, and shortness of breath also characterize bronchiectasis exacerbations. Focal crackles may also be present on physical examination. Distinguishing features from CAP include known history of bronchiectasis, chronic baseline respiratory symptoms, and/or thickened airways on chest imaging. (See  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a>.) </p><p></p><p>Noninfectious illnesses that mimic or co-occur with CAP and present with pulmonary opacities and cough include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure with pulmonary edema</strong> – Cough accompanied by shortness of breath, particularly with exertion or when lying flat, should raise suspicion for heart failure. Physical examination findings such as an elevated jugular venous pressure, bilateral basilar crackles with resonance to percussion, S3 heart sound, displaced apical impulse, and peripheral edema should further heighten suspicion. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary embolism (PE)</strong> – Dyspnea, pleuritic chest pain, and hemoptysis in addition to cough are classic symptoms associated with PE. However, presenting symptoms vary and can be mild and nonspecific. History may be notable for malignancy, recent surgery, or prolonged immobilization. Physical examination findings also vary but those that support this diagnosis include tachypnea, tachycardia, and unilateral lower extremity swelling. Any suspicion for PE warrants further evaluation. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung cancer </strong>–<strong> </strong>Lung cancer is an uncommon cause of acute shortness of breath and cough but should be considered in any current or prior smoker. Features that should raise suspicion for this diagnosis include a recent change in a chronic "smoker's cough," hemoptysis, and signs of focal airway obstruction on physical examination such as a unilateral wheeze or decreased breath sounds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atelectasis </strong>–<strong> </strong>Atelectasis refers to collapse of a portion of the pulmonary parenchyma and can appear similar to pneumonia on chest imaging. (See  <a class="medical medical_review" href="/d/html/6978.html" rel="external">"Atelectasis: Types and pathogenesis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspiration or chemical pneumonitis – </strong>Aspiration of substances that are toxic to the lower airways (eg, gastric acid, stomach contents) can lead to inflammation and opacities on chest imaging. Imaging abnormalities are typically seen in the gravity-dependent areas of the lung (eg, bases of lower lobes if upright, posterior segments of lower lobes if supine). In contrast to aspiration pneumonia, clinical improvement is often rapid following aspiration or chemical pneumonitis. (See  <a class="medical medical_review" href="/d/html/7024.html" rel="external">"Aspiration pneumonia in adults", section on 'Chemical pneumonitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>E-cigarette or vaping product use associated lung injury (EVALI) </strong>– EVALI should be considered in patients with respiratory complains and recent e-cigarette use. Respiratory symptoms are similar to CAP and include fever, cough, shortness of breath, and chest pain. Concurrent gastrointestinal symptoms (eg, nausea, vomiting, diarrhea, and abdominal pain) are also common. (See  <a class="medical medical_review" href="/d/html/122671.html" rel="external">"E-cigarette or vaping product use-associated lung injury (EVALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug reactions</strong> –<strong> </strong>Exposure to certain drugs can cause hypersensitivity reactions or direct pulmonary toxicity. Symptoms are often similar to CAP, but the acuity of onset, pathogenesis, and radiographic appearance vary by agent. Common culprits include <a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>. (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial lung diseases (ILD) </strong>–<strong> </strong>A wide variety of ILD can present similarly to CAP early in their evolution and include sarcoidosis, asbestosis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia, and systemic rheumatic diseases (eg, granulomatosis with polyangiitis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis). (See  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p></p><p>Febrile illness and/or sepsis can also be the presenting syndrome in patients with CAP; other common causes of these syndromes include urinary tract infections, intra-abdominal infections, and endocarditis.</p><p>In all cases, monitoring the patient’s progress over time helps confirm or refute the initial diagnosis. For example, the rapid resolution of pulmonary opacities on chest imaging suggests a noninfectious process such as pulmonary edema or atelectasis. Conversely, lack of response to empiric treatment in 48 to 72 hours suggest that initial antibiotic selection was inadequate, there are complications, or that there is an alternate diagnosis. (See <a class="local">'Follow-up care'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">CHEST IMAGING FINDINGS</span></p><p class="headingAnchor" id="H2289539863"><span class="h2">Imaging techniques</span><span class="headingEndMark"> — </span>Chest imaging is indicated for the majority of patients with suspected CAP to confirm the diagnosis, assess for complications (eg, parapneumonic effusion, empyema, abscess), and evaluate for alternate or concurrent diagnosis (eg, heart failure, malignancy). The presence of an opacity on chest imaging in a patient with a compatible clinical syndrome is the gold standard for diagnosis and recommended for diagnosis in the American Thoracic Society/Infectious Disease Society of America guidelines [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H2810109188"><span class="h3">Chest radiograph (preferred)</span><span class="headingEndMark"> — </span>The presence of an infiltrate on plain chest radiograph is considered the gold standard for diagnosing pneumonia when clinical and microbiologic features are supportive. For most patients with suspected CAP, obtaining posteroanterior and lateral chest radiographs is sufficient for diagnosis. Rarely, we forgo imaging in outpatients with highly compatible syndromes (eg, acute onset, fever, cough, shortness of breath, and signs of consolidation on physical examination) and lack of concern for other causes. Imaging is a necessity for hospitalized patients.</p><p>Radiographic findings consistent with the diagnosis of CAP include lobar consolidations  (<a class="graphic graphic_diagnosticimage graphicRef65658 graphicRef64692" href="/d/graphic/65658.html" rel="external">image 1A-B</a>), interstitial infiltrates  (<a class="graphic graphic_diagnosticimage graphicRef116892 graphicRef86363 graphicRef62313" href="/d/graphic/116892.html" rel="external">image 2A-C</a>), and/or cavitations  (<a class="graphic graphic_diagnosticimage graphicRef53664" href="/d/graphic/53664.html" rel="external">image 3</a>). Although certain radiographic features suggest specific causes of pneumonia (eg, lobar consolidations suggest infection with typical bacterial pathogens), radiographic appearance alone cannot reliably differentiate among etiologies [<a href="#rid5">5,27</a>]. There is also substantial interobserver variation in the interpretation of chest radiographs in patients with possible pneumonia between different radiologists [<a href="#rid28">28-30</a>] and between emergency department physicians and radiologists [<a href="#rid31">31,32</a>].</p><p>In some cases, chest radiographs may not be sufficiently sensitive for the detection of pneumonia [<a href="#rid2">2,33</a>]. There are case reports and animal experiments favoring the hypothesis that volume depletion may produce an initially negative radiograph, which "blossoms" into infiltrates following rehydration [<a href="#rid34">34</a>]. In support of this hypothesis, one population-based cohort study of suspected CAP found that 7 percent of patients with negative initial radiographs developed changes consistent with CAP on repeat chest radiograph [<a href="#rid35">35</a>].</p><p>Thus, when clinical suspicion is high despite a negative chest radiograph, we decide to either treat empirically and/or perform a chest computed tomography (CT) depending on the patient’s severity of illness, immune status, and/or the suspected pathogen. When clinical suspicion is lower, we determine the need for additional chest imaging (eg, CT scan) or other workup based on the most likely potential causes in each individual (eg, CT pulmonary angiogram for evaluation of pulmonary embolism). </p><p class="headingAnchor" id="H458385101"><span class="h3">Computed tomography (CT) scan</span><span class="headingEndMark"> — </span>High-resolution CT is more sensitive for the detection of pneumonia than chest radiograph [<a href="#rid2">2,36,37</a>]. CT scanning can be helpful to better characterize pneumonia and identify complications [<a href="#rid36">36,38</a>]. This is particularly true for immunocompromised patients who are at risk for infection with broad array of pathogens. The enhanced sensitivity and specificity of CT scan can help distinguish among causes (eg, invasive fungal infections, pneumocystis pneumonia, bacterial pathogens) [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p>We also obtain chest CT for selected patients in whom CAP is suspected based on clinical features despite a negative chest radiograph to help confirm the diagnosis and assess for other causes of symptoms. (See <a class="local">'Chest radiograph (preferred)'</a> above.)</p><p>Chest CT can also be helpful to rule out pneumonia in patients with equivocal clinical syndromes and nondiagnostic chest radiographs (opacities present but not clear if due to pneumonia versus pulmonary edema, atelectasis, contusion, chronic lung disease, or other etiologies). This is most common in patients with multiple comorbidities presenting with nonspecific syndromes. A chest CT in such cases can help rule out pneumonia in up to 50 percent of cases [<a href="#rid2">2</a>].  </p><p class="headingAnchor" id="H312994270"><span class="h3">Ultrasound and other studies</span><span class="headingEndMark"> — </span>There are increasing data on the use of lung ultrasound to diagnose pneumonia, particularly in unstable patients in the emergency department or intensive care unit in whom it is difficult to obtain good-quality chest radiographs. In three large meta-analyses, the sensitivity of lung ultrasound was approximately 80 to 90 percent and the specificity approximately 70 to 90 percent [<a href="#rid40">40-42</a>]. Diagnostic performance can vary, however, depending on the ultrasonographer's level of experience [<a href="#rid43">43</a>]. It is therefore reasonable for those with experience performing lung ultrasounds to use this modality when a chest radiograph is not likely to be a good-quality study.</p><p class="headingAnchor" id="H928618758"><span class="h1">DETERMINING SITE OF CARE</span><span class="headingEndMark"> — </span>For patients with a working diagnosis of CAP, the next steps in management are defining the severity of illness and determining the most appropriate site of care. Determining the severity of illness is based on clinical judgement and can be supplemented by use of severity scores  (<a class="graphic graphic_algorithm graphicRef113076" data-inline-graphics="113076" href="/d/graphic/113076.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/7022.html" rel="external">"Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120057">(Related Pathway(s):  <a class="utd-content-120057" href="/pathway/120057?topicRef=7032&amp;source=see_link">Community-acquired pneumonia: Determining the appropriate site of care for adults</a>.)</span></p><p>The triage of patients with known or suspected coronavirus disease 2019 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MICROBIOLOGIC TESTING</span></p><p class="headingAnchor" id="H2246754425"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>The benefit of obtaining a microbiologic diagnosis should be balanced against the time and cost associated with an extensive evaluation in each patient. Apart from testing all patients for COVID-19 during the pandemic, we generally take a tiered approach to microbiologic evaluation based on CAP severity and the site of care  (<a class="graphic graphic_table graphicRef118966" data-inline-graphics="118966" href="/d/graphic/118966.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most patients with mild CAP being treated in the ambulatory setting</strong>, microbiologic testing is not needed apart from COVID-19 testing during the pandemic. Testing for influenza can also be considered when community incidence is high and when results would change management (eg, those who meet criteria for antiviral treatment) [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Diagnostic testing for outpatients with mild CAP is otherwise generally unnecessary since empiric antibiotic therapy is generally successful, and knowledge of the infecting pathogen does not usually improve outcomes [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most patients with moderate CAP admitted to the general medical ward,</strong> we obtain the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood cultures </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sputum Gram stain and culture </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinary antigen testing for <em>Streptococcus</em> <em>pneumoniae</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testing for <em>Legionella </em>spp (polymerase chain reaction [PCR] when available, urinary antigen test as an alternate)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>COVID-19 testing </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testing for respiratory viruses during respiratory virus season (PCR preferred, particularly for influenza)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid nasal PCR or culture for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in patients with risk factors for MRSA, severe disease, or a biphasic illness (viral respiratory syndrome followed by new deterioration) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A screening test for human immunodeficiency virus (HIV) infection</p><p></p><p class="bulletIndent1">Blood and urine cultures should ideally be performed before the start of empiric antibiotics. To help improve the diagnostic yield of sputum, patients should rinse their mouth and cough deeply before expectoration. The sample should be inoculated on culture media as soon as possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most hospitalized patients with severe CAP, including those admitted to the intensive care unit</strong>, we obtain the tests bulleted above. In addition, for patients with severe disease who fail to respond to empiric therapy, we obtain bronchoscopic specimens for microbiologic testing when feasible, weighing the benefits of obtaining a microbiologic diagnosis against the risks of the procedure (eg, need for intubation, bleeding, bronchospasm, pneumothorax) on a case-by-case basis. When pursuing bronchoscopy, we usually send specimens for aerobic culture, <em>Legionella</em> culture, fungal stain and culture, pneumocystis pneumonia stain, or PCR if there is concern for impaired immunity, and test for respiratory viruses using multiplex PCR panels. </p><p></p><p>In all cases, we modify this approach based on epidemiologic exposures, patient risk factors/clinical features, public health needs, and the likelihood that the test results would help refine the differential diagnosis and/or change management. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with known or probable exposures to epidemic pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome (MERS), <em>Legionella</em>, or Avian influenza viruses, we ensure that our evaluation includes tests for these pathogens. (See <a class="local">'Important pathogens'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cavitary pneumonia, we may include testing for tuberculosis, fungal pathogens, and <em>Nocardia</em>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompromised patients, we broaden our differential to include opportunistic pathogens such as <em>Pneumocystis jirovecii</em>, fungal pathogens, parasites, and less common viral pathogens such as cytomegalovirus. The approach to diagnostic testing varies based on the type and degree of immunosuppression and other patient-specific factors. (See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a> and  <a class="medical medical_review" href="/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a>.)</p><p></p><p>Making a microbiologic diagnosis also allows for directed therapy, which has been shown to improve outcomes [<a href="#rid47">47-49</a>], and can also limit antibiotic overuse and prevent antimicrobial resistance and unnecessary complications, such as <em>Clostridioides </em>(formerly <em>Clostridium</em>) <em>difficile</em> infections. Microbiologic test results are also critical for defining the local epidemiology and antimicrobial resistance patterns, which guide the care of other patients. In addition, a negative evaluation can help support a decision to narrow or discontinue antibiotic treatment. When defining the scope of our microbiologic evaluation, we also take the certainty of the diagnosis of CAP into consideration. Because a substantial portion of patients hospitalized with an initial clinical diagnosis of CAP are ultimately found to have alternate diagnoses [<a href="#rid4">4</a>], pursuing a comprehensive microbiologic evaluation can help reach the final diagnosis. </p><p>Our approach is similar to that of the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines, which does not routinely recommend microbiologic testing for outpatients with CAP (outside of the pandemic) [<a href="#rid1">1</a>]. However, the ATS/IDSA is more conservative in its approach for hospitalized patients. </p><p>Blood cultures, sputum Gram stain and culture, and MRSA nasal testing are recommended for hospitalized patients with severe CAP, concern for infection with MRSA or <em>Pseudomonas, </em>or recent hospitalization and/or receipt of IV antibiotics. </p><p>The ATS/IDSA recommends reserving testing for <em>Legionella </em>spp and urine pneumococcal antigen testing for patients with severe CAP, compromised immune systems, or epidemiologic exposures. </p><p>For other hospitalized patients, the ATS/IDSA neither recommends for nor against obtaining sputum Gram stain and culture but states that the decision should be individualized based on clinical presentation, local epidemiology, and antimicrobial stewardship processes. The differences in approaches may be in part due to a difference in vantage point; the ATS/IDSA guidelines address patients with known CAP [<a href="#rid1">1</a>], whereas this topic addresses the evaluation of an undifferentiated patient in whom CAP is suspected.</p><p>Overall, the utility of pursuing a microbiologic evaluation has been debated in the literature, with some studies indicating that diagnostic yield from testing is low and rarely changes management, while other studies suggest that establishing a diagnosis provides diagnostic clarity, can help tailor the treatment strategy, and provides valuable data at the population level on prevailing pathogens and antibiotic-resistance profiles [<a href="#rid50">50,51</a>]. In practice, most hospitalized patients are treated empirically without a microbiologic diagnosis [<a href="#rid52">52-54</a>]. </p><p class="headingAnchor" id="H5"><span class="h2">Important pathogens</span><span class="headingEndMark"> — </span>Certain pathogens are critical to detect because they represent important epidemiologic challenges, serious conditions that require treatment that differs from standard empiric regimens, and/or require special measures to prevent transmission from infected patients to staff and other patients. These organisms include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe acute respiratory syndrome coronavirus 2 </strong>– The epidemiology of SARS-CoV-2, the virus that causes COVID-19, is discussed separately. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community-acquired methicillin-resistant </strong><strong><em>S. aureus </em></strong><strong>(CA-MRSA)</strong> – Because CA-MRSA infections can be severe and some but not all empiric treatment regimens cover CA-MRSA, it is important to make the diagnosis. Features that raise suspicion for CA-MRSA include concurrent or prior influenza infection [<a href="#rid55">55</a>], necrotizing pneumonia, or other rapidly progressive pneumonia, particular occurring in young adults. The presence of gram-positive cocci on a high-quality sputum Gram stain and/or positive nasal MRSA test further raise suspicion. The diagnosis is confirmed by culture with susceptibility testing. (See  <a class="medical medical_review" href="/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology", section on 'Community-associated MRSA infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Legionella </em></strong><strong>spp</strong><em> – </em>Detection of <em>Legionella</em> has important public health implications and can inform treatment selection. While there are no distinguishing clinical features, known outbreaks or family clusters (often related to contaminated water sources) should raise suspicion. Recent travel is a risk factor. The diagnosis can be made by urine antigen testing (limited to serogroup 1), PCR, or culture on special media. (See  <a class="medical medical_review" href="/d/html/7035.html" rel="external">"Clinical manifestations and diagnosis of <i>Legionella </i>infection"</a> and  <a class="medical medical_review" href="/d/html/7025.html" rel="external">"Treatment and prevention of <i>Legionella</i> infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza and other respiratory viruses </strong>– Influenza and other respiratory viruses are important to recognize because of the need for appropriate infection control in hospitalized patients, for public health reporting purposes, and for rapid treatment with antiviral agents in the cases of influenza and SARS-CoV-2. During influenza outbreaks, outpatients with compatible syndromes can be diagnosed on clinical grounds alone. Real-time reverse-transcriptase PCR is the test of choice to diagnose influenza but requires a laboratory and a laboratory technician. Rapid point-of-care diagnostic tests can be done in an emergency department or office without a laboratory technician; these tests show a sensitivity of only about 50 to 60 percent, but specificity is &gt;95 percent, so a positive test helps establish the diagnosis but a negative result does not rule out influenza [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1">The need to know the influenza type depends partly on whether multiple influenza strains with different resistance patterns are circulating. For example, the majority of seasonal influenza H1N1 during the 2008 to 2009 season were resistant to <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a>, but almost all isolates of H1N1 influenza since the 2009 pandemic have been susceptible to oseltamivir [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7008.html" rel="external">"Antiviral drugs for influenza: Pharmacology and resistance"</a>.)</p><p></p><p class="bulletIndent1">For severe and sporadic cases of influenza-like illness, there is more urgency to make a specific diagnosis due to concern for avian influenza A H5N1, avian influenza A H7N9, or other emerging strains. In such situations, PCR for influenza is appropriate [<a href="#rid56">56</a>]. Reagents to test for novel influenza strains when they first emerge may be available only in public health laboratories; local hospital laboratory supervisors and infection control practitioners will know the specimen referral process. (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7002.html" rel="external">"Avian influenza: Epidemiology and transmission"</a> and  <a class="medical medical_review" href="/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zoonotic pathogens</strong> – Several pathogens have emerged from animal sources to cause outbreaks of respiratory disease in humans (eg, H1N1 pandemic influenza, H5N1 avian influenza, H7N9 avian influenza, SARS-CoV-2, MERS-CoV). Other zoonotic pathogens that can cause respiratory disease in humans include hantaviruses (eg, Sin Nombre virus) and <em>Y</em>ersinia<em> pestis</em>; such pathogens should be considered in patients with relevant travel or exposure history [<a href="#rid60">60,61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents of bioterrorism</strong> – Agents of bioterrorism that can cause a pneumonic syndrome include <em>Bacillus anthracis</em> (inhalational anthrax), <em>Y. pestis</em> (pneumonic plague), <em>Francisella tularensis</em> (tularemia), <em>Coxiella burnetii</em> (Q fever), <em>Legionella</em> spp, influenza virus, hantavirus, and ricin  (<a class="graphic graphic_table graphicRef56078" href="/d/graphic/56078.html" rel="external">table 3</a>) [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/2735.html" rel="external">"Identifying and managing casualties of biological terrorism"</a>.)</p><p></p><p class="headingAnchor" id="H3115618465"><span class="h2">Diagnostic tests</span></p><p class="headingAnchor" id="H8"><span class="h3">Blood cultures</span><span class="headingEndMark"> — </span>We typically obtain two sets of blood cultures in patients hospitalized with CAP at the time the initial working diagnosis is established. To enhance diagnostic yield, blood cultures should ideally be obtained prior to empiric antibiotic administration. Although the value of obtaining blood cultures for all hospitalized patients is debated [<a href="#rid1">1</a>], results both help direct patient care and inform important public health programs. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients, a positive culture with a likely pathogen (eg,<em> S. pneumoniae</em>) provides a definitive microbiologic diagnosis and allows for directed therapy, which has been shown to improve outcomes [<a href="#rid47">47-49</a>] and minimize potential adverse effects from unnecessary antibiotic exposure. In addition, blood cultures also help identify complications (eg, bacteremia) or alternate diagnoses (eg, endocarditis), which might have otherwise gone undetected. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For many health care institutions, blood culture data is the primary source for microbiologic data used to inform institutional antibiograms and antimicrobial stewardship efforts. At the national level, isolates identified serve as an important resource for tracking resistance patterns of <em>S. pneumoniae </em>and other common pathogens (eg, the United States Centers for Disease Control and Prevention surveillance network is reliant on blood culture data [<a href="#rid63">63</a>]). These are the data used for evaluating efficacy of current <em>S. pneumoniae</em> vaccines and the serotypes needed for inclusion in future vaccines [<a href="#rid64">64-66</a>]. </p><p></p><p>The major downsides of obtaining blood cultures include their low diagnostic yield and the low degree of certainty that results improve clinical outcomes. The rate of positive blood cultures ranges from approximately 4.7 to 16 percent among patients hospitalized with CAP [<a href="#rid67">67-75</a>]. In one retrospective cohort study in the United States evaluating &gt;130,000 patients with pneumonia, blood cultures were positive in 4.7 percent (though an uncertain percentage were obtained while on antibiotics); the likelihood of a positive culture rose with the severity of illness [<a href="#rid74">74</a>]. <em>S. pneumoniae</em> is the most common blood culture isolate (approximately 33 percent), followed by <em>S. aureus</em> and <em>Pseudomonas</em> <em>aeruginosa</em>. Approximately two-thirds of isolates were resistant to first-line CAP treatment regimens. While the degree to which culture results lead to changes in management that improve outcomes is not well studied, available data suggest that the number might be low [<a href="#rid69">69,72</a>]. In one study, with a 10 percent rate of false-positive cultures, hospital stays were prolonged due to a perceived need for <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> to treat <em>S. aureus</em>, when the laboratory calls to report gram-positive cocci, which were actually coagulase-negative staphylococci that had yet to be identified. </p><p class="headingAnchor" id="H9"><span class="h3">Sputum Gram stain and culture</span><span class="headingEndMark"> — </span>We generally obtain a sputum Gram stain and culture for most hospitalized patients with CAP because results can help direct therapy and reduce antibiotic overuse. To enhance diagnostic yield, specimens should ideally be from a deep cough, obtained before antibiotics, and processed within two hours of collection [<a href="#rid76">76</a>]. </p><p>Culture results should be interpreted based on the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Quantitation of growth (heavy, moderate, or light)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical correlation</p><p class="bulletIndent1"><span class="glyph">●</span>Correlation with the Gram stain</p><p class="bulletIndent1"><span class="glyph">●</span>Quality of the specimen</p><p></p><p>True pathogens are generally present in moderate or heavy amounts by Gram stain and culture. However, certain pathogens are regarded as significant regardless of concentration, including <em>Legionella</em> spp, <em>B. anthracis</em>, <em>Mycobacterium tuberculosis</em>, <em>Mycoplasma pneumoniae</em>, <em>Chlamydia pneumoniae</em>, and <em>Chlamydia psittaci</em>; these respiratory pathogens are virtually never colonizers but always represent disease.</p><p>Antibiotics may alter the yield of any subsequent culture of respiratory secretions [<a href="#rid77">77</a>]. Specimens collected after antibiotics are given are more likely to grow <em>S. aureus</em> or gram-negative bacilli (GNB), which usually represent early airway colonizers.</p><p>When <em>S. pneumoniae</em> or <em>Haemophilus influenzae</em> are the etiologic agent, false-negative cultures may occur because of their fastidious growth requirements and the lack of selective media. By contrast, <em>S. aureus</em> and GNB are relatively rare pulmonary pathogens that are easily grown in respiratory secretions because they are hardy and easily recognized by growth on selective media. The failure to grow these organisms is strong evidence against their presence.</p><p>A "good-quality" sputum sample is one with moderate or many polymorphonuclear leukocytes but few (or no) squamous epithelial cells on Gram stain. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7018.html" rel="external">"Sputum cultures for the evaluation of bacterial pneumonia", section on 'Expectorated sputum'</a>.)</p><p>The utility of sputum Gram stain and culture is debated. Rates of pathogen detection and impact on clinical outcomes vary among studies [<a href="#rid50">50,52,78-83</a>]. One meta-analysis evaluating 24 studies including &gt;4500 patients detected bacterial pathogens in 73 percent of good-quality sputum Gram stains (95% credible interval [CrI] 26-96 percent); detection rates dropped to 36 percent (95% CrI 22-53 percent) when including lower quality Grain stains as well [<a href="#rid50">50</a>]. The diagnostic yield was highest for <em>S. pneumoniae</em> (sensitivity 69 percent [95% CrI 56-80 percent]; specificity 91 percent [95% CrI 83-96 percent]) and <em>H. influenzae</em> (sensitivity 76 percent [95% CrI 60-87 percent]; specificity of 97 percent [95% CrI 91–99 percent]). Other studies have found detection rates &lt;10 percent [<a href="#rid52">52,78,79</a>]. Differences among studies may be due to variations in specimen quality, timeliness of specimen processing, clinical microbiology laboratory capabilities, and whether patients were exposed to antibiotics before sampling. The widespread use of broad-spectrum empiric treatments before Gram stain and culture return also likely blunts capacity to assess the specific impact of Gram stain and culture guided therapy.  </p><p class="headingAnchor" id="H10"><span class="h3">Urine pneumococcal antigen testing</span><span class="headingEndMark"> — </span>We generally send the urine <em>S. pneumoniae</em> antigen test in most hospitalized patients with pneumonia because the test is easy to obtain, turnaround time is rapid, and results are less affected by antibiotic administration when compared with Gram stain and culture. As with other microbiologic tests, when positive, results help direct therapy and reduce antibiotic overuse. The urine <em>S. pneumoniae</em> antigen assay has a sensitivity of &gt;70 percent and a specificity of approximately 98 percent. The diagnostic approach for pneumococcal pneumonia, including the performance characteristics of this assay, are discussed separately. (See  <a class="medical medical_review" href="/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H587264652"><span class="h3">Testing for Legionella</span><span class="headingEndMark"> — </span>We also test for infection with <em>Legionella</em> spp in most hospitalized patients. The main testing options for <em>Legionella</em> infection include nucleic acid detection (eg, PCR), urine antigen tests, and culture  (<a class="graphic graphic_table graphicRef69022" href="/d/graphic/69022.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>When testing for <em>Legionella </em>in patients with pneumonia, we prefer to use PCR on a lower respiratory tract sample (eg, sputum or bronchoalveolar lavage specimen) because PCR has high diagnostic accuracy and detects all <em>Legionella</em> species and serogroups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If PCR is not available or if sputum cannot be obtained, urine antigen testing is an acceptable alternative, especially in regions such as the United States where the prevalence of <em>Legionella pneumophila </em>serogroup 1 is high. The main advantages of the urinary antigen test are its rapid turnaround time and high specificity. A key disadvantage of the urine <em>Legionella </em>assay is that it does not detect all <em>L. pneumophila</em> serotypes or other <em>Legionella</em> species.</p><p></p><p>Because the urinary antigen test only detects <em>L. pneumophila </em>serotype 1, we generally send PCR or culture on a lower respiratory tract sample when urine antigen assays are negative and <em>Legionella </em>infection is still suspected (eg, patients with severe bilateral interstitial pneumonia, particularly if immunocompromised). For patients with positive <em>Legionella</em> urinary antigen tests or PCR, we generally also obtain a culture from the lower respiratory tract for epidemiologic purposes (eg, comparison with isolates from other patients or potential sources). Testing for Legionella infection is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7035.html" rel="external">"Clinical manifestations and diagnosis of <i>Legionella </i>infection", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2232499383"><span class="h3">Testing for respiratory viruses</span></p><p class="headingAnchor" id="H3708436396"><span class="h4">Coronavirus disease 2019 testing</span><span class="headingEndMark"> — </span>During the pandemic, we test all patients with known or suspected CAP for COVID-19, regardless of treatment setting. Testing for COVID-19 is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p class="headingAnchor" id="H2956893461"><span class="h4">Other respiratory viruses</span><span class="headingEndMark"> — </span>During respiratory virus season (eg, late fall to early spring in the northern hemisphere), we also test for a broad array of respiratory viruses (eg, influenza, adenovirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, and rhinovirus) in all hospitalized patients. Apart from influenza and SARS-CoV-2, we generally do not test for respiratory viruses in outpatients. </p><p>When testing for influenza, PCR is preferred over rapid antigen testing. For other respiratory viruses, the types of assays available (eg, direct PCR, multiplex PCR, antigen-detection, serology, culture) vary among institutions. In some cases, multiplex PCR panels that test for a wide array of viral and bacterial pathogens are used. Care should be taken when interpreting results. While respiratory viruses are increasingly recognized as a cause of CAP, they can also serve as cofactors for bacterial infection and can be asymptomatic colonizers. Thus, a positive result does not exclude bacterial coinfection. Similarly, negative results do not exclude a viral pathogen, particularly if only obtaining an upper respiratory tract specimen from a patient with lower respiratory tract disease [<a href="#rid84">84,85</a>]. The overall impact of viral testing on patient outcomes and limiting antibiotic use is thus far limited [<a href="#rid86">86,87</a>]. </p><p>Performance characteristics of individual respiratory viral diagnostic assays are discussed separately. (See  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults"</a> and  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"</a> and  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections"</a> and  <a class="medical medical_review" href="/d/html/8348.html" rel="external">"Diagnosis, treatment, and prevention of adenovirus infection", section on 'Pneumonia'</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p>Our approach is similar to that of the ATS/IDSA guidelines, which do not recommend testing for respiratory viruses (apart from influenza and SARS-CoV-2) in outpatients [<a href="#rid88">88</a>]. For hospitalized patients, the guidelines reserve testing for respiratory viruses (apart from influenza and SARS-CoV-2) for patients with severe CAP and immunocompromised patients. </p><p class="headingAnchor" id="H918758782"><span class="h3">Differentiating viral from bacterial CAP</span><span class="headingEndMark"> — </span>There is no single clinical feature, radiographic finding, or test that can reliably distinguish viral from bacterial pneumonia  (<a class="graphic graphic_figure graphicRef140359" data-inline-graphics="140359" href="/d/graphic/140359.html" rel="external">figure 2</a>). However, in combination, the following findings are highly suggestive of viral pneumonia:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive viral test (eg a positive influenza PCR)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low procalcitonin level (typically &lt;0.25 ng/mL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of microbiologic evidence of bacterial infection (eg, negative blood and sputum cultures and/or urine antigen testing)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of radiographic findings that suggest bacterial infection (eg, dense lobar consolidations, alveolar consolidations with air bronchograms)</p><p></p><p>Because viruses are estimated to cause 30 to 50 percent of CAP cases [<a href="#rid89">89,90</a>], when these findings occur in combination in a patient who is stable or improving, it is reasonable to stop antibiotics early. </p><p>Our approach to using procalcitonin to guide antibiotic discontinuation in patients with CAP is reflected in this algorithm  (<a class="graphic graphic_algorithm graphicRef117052" href="/d/graphic/117052.html" rel="external">algorithm 2</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Community-acquired pneumonia in hospitalized patients'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Multiplex molecular assays</span><span class="headingEndMark"> — </span>Molecular assays that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample are being increasingly used [<a href="#rid91">91</a>]. How these assays are used in practice varies widely among institutions. In some institutions where multiplex panels are available on site, these assays are used routinely for initial diagnosis. In other institutions, use of these panels is reserved for patients with severe pneumonia, immunocompromised patients, or for those who fail to respond to initial empiric therapy. </p><p>The most commonly available multiplex assays include the BioFire FilmArray Pneumonia Panel (PN panel) and Pneumonia Plus Panel (PNplus panel), which are US Food and Drug Administration-cleared for use on lower respiratory tract specimens (sputum and bronchoalveolar lavage fluid). Each detects a broad range of bacterial and viral pathogens (including <em>C.</em> <em>pneumoniae,</em> <em>M. pneumoniae, Bordetella pertussis, </em>influenza, respiratory syncytial virus, parainfluenza, adenovirus, coronavirus, metapneumovirus, and others) and certain antimicrobial resistance markers. Several studies suggest that results from these multiplex panels are largely concordant with conventional culture [<a href="#rid92">92-94</a>], though further study is needed to confirm concordance. </p><p>While use of multiplex panels increases the likelihood of detecting a micro-organism in a respiratory tract sample [<a href="#rid95">95-97</a>], the predictive value of these results is not clear. As an example, the detection of a viral pathogen does not rule out the possibility of bacterial coinfection (both bacteria and viruses are identified in approximately 5 to 10 percent of CAP with an identified etiology) [<a href="#rid89">89</a>]. Similarly, some viral and bacterial pathogens can colonize the airways; their detection does not definitively indicate infection. In sum, while these assays are promising, the true impact of multiplex molecular assays on patient outcomes is yet to be substantiated by data. </p><p class="headingAnchor" id="H2239971830"><span class="h1">FOLLOW-UP CARE</span></p><p class="headingAnchor" id="H1174140770"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>Because a substantial portion of patients initially diagnosed with CAP will ultimately be found to have an alternate diagnosis, close follow-up is important for both outpatient and hospitalized patients  (<a class="graphic graphic_algorithm graphicRef131728" data-inline-graphics="131728" href="/d/graphic/131728.html" rel="external">algorithm 3</a>). </p><p>Most patients will show some signs of improvement within 48 to 72 hours of starting treatment. Subjectively, we look for improvement in cough, sputum production, dyspnea, and chest pain. Objectively, we assess for resolution of fever and normalization of heart rate, respiratory rate, oxygenation, and white blood cell count. Generally, patients demonstrate some clinical improvement within 48 to 72 hours. </p><p>Both failure to improve and very rapid response should raise suspicion for diagnoses other than CAP. Reasons for clinical failure can generally be categorized as either progression of initial infection (eg, overwhelming infection despite appropriate antibiotics, infection with a drug resistant pathogen) or development of complications (eg, lung abscess, empyema, heart failure, other cardiac events). </p><p>By contrast, rapid resolution of pulmonary infiltrates on chest imaging also suggests an alternate, and usually noninfectious etiology. Pulmonary infiltrates in CAP are primarily caused by the accumulation of white blood cells in the alveolar space and typically take weeks to resolve. </p><p>These concepts are discussed further elsewhere. (See  <a class="medical medical_review" href="/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults", section on 'Complications and prognosis'</a> and  <a class="medical medical_review" href="/d/html/6992.html" rel="external">"Nonresolving pneumonia"</a>.)</p><p class="headingAnchor" id="H3924424515"><span class="h2">Follow-up imaging</span><span class="headingEndMark"> — </span>Most patients with prompt clinical resolution after treatment do not require a follow-up chest radiograph as radiographic response lags behind clinical response [<a href="#rid98">98</a>]. However, follow-up clinic visits are good opportunities to review the patient's risk for lung cancer based on age, smoking history, and recent imaging findings  (<a class="graphic graphic_algorithm graphicRef131579" data-inline-graphics="131579" href="/d/graphic/131579.html" rel="external">algorithm 4</a>).</p><p>This approach is similar to that outlined by the American Thoracic Society (ATS)/Infectious Diseases Society of America, which recommend not obtaining a follow-up chest radiograph in patients whose symptoms have resolved within five to seven days [<a href="#rid1">1</a>]. </p><p>Most available studies have evaluated whether short-term follow-up imaging detects previously undiagnosed lung cancer [<a href="#rid99">99-102</a>]. The overall diagnostic yield is low in these studies (&lt;5 percent), and the benefit appears greatest in those with risk factors for lung cancer (ie, males aged &gt;50 with substantial smoking history) who otherwise meet criteria for screening via computed tomography. We therefore only recommend follow-up imaging for patients who independently meet criteria for lung cancer screening. (See  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H2627733783"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15374.html" rel="external">"Patient education: Pneumonia in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4002.html" rel="external">"Patient education: Pneumonia in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> − The diagnosis of community-acquired pneumonia (CAP) generally requires the demonstration of an opacity on chest imaging in a patient with a clinically compatible syndrome (eg, fever, dyspnea, cough, and sputum production). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with suspected CAP, we obtain posteroanterior and lateral chest radiographs alone. In selected cases, if clinical suspicion for CAP is high but chest imaging is negative, we obtain a chest computed tomography (CT). Similarly, chest CT can help rule out pneumonia in patients with only moderate suspicion for pneumonia but nondiagnostic chest radiographs. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rarely, we make the diagnosis of CAP based on clinical features alone. We typically reserve this option for outpatients who have a highly compatible syndrome (eg, fever, dyspnea, cough, tachycardia, crackles on chest auscultation, and oxygen saturation &lt;95 percent) who lack concern for other causes, or when chest radiography is not available. Because clinical features alone have limited diagnostic accuracy, we generally follow these patients closely to ensure they are improving with treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest imaging</strong> − Radiographic findings consistent with the diagnosis of CAP include lobar consolidations  (<a class="graphic graphic_diagnosticimage graphicRef65658 graphicRef64692" href="/d/graphic/65658.html" rel="external">image 1A-B</a>), interstitial infiltrates  (<a class="graphic graphic_diagnosticimage graphicRef116892 graphicRef86363 graphicRef62313" href="/d/graphic/116892.html" rel="external">image 2A-C</a>), and/or cavitations  (<a class="graphic graphic_diagnosticimage graphicRef53664" href="/d/graphic/53664.html" rel="external">image 3</a>). Although certain radiographic features suggest specific causes of pneumonia (eg, lobar consolidations suggest infection with typical bacterial pathogens), radiographic appearance alone cannot reliably differentiate among etiologies  (<a class="graphic graphic_figure graphicRef140359" href="/d/graphic/140359.html" rel="external">figure 2</a>). (See <a class="local">'Chest imaging findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial working diagnosis</strong> − Once an initial working diagnosis is made, the next step is to determine the most appropriate site of care. Typically, the decision is made based on clinical judgement and can be supplemented by clinical prediction rules  (<a class="graphic graphic_algorithm graphicRef113076" href="/d/graphic/113076.html" rel="external">algorithm 1</a>). (See <a class="local">'Determining site of care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic testing</strong> − The need for microbiologic testing varies based on the severity of illness and clinical suspicion for specific pathogens (eg, outbreak pathogens, methicillin-resistant <em>Staphylococcus aureus</em>, etc). Generally, we take a tiered approach to testing based on site of care  (<a class="graphic graphic_table graphicRef118966" href="/d/graphic/118966.html" rel="external">table 1</a>). (See <a class="local">'Microbiologic testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with mild CAP being treated in the ambulatory setting, microbiologic testing is not needed apart from COVID-19 testing during the pandemic. Testing for influenza can also be considered when community incidence is high and when results would change management (eg, those who meet criteria for antiviral treatment). (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with moderate CAP admitted to the general medical ward, we obtain the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Blood cultures (ideally before antibiotics)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sputum Gram stain and culture </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Urinary antigen testing for <em>Streptococcus</em> <em>pneumoniae</em></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testing for <em>Legionella </em>spp (polymerase chain reaction [PCR] when available, urinary antigen test as an alternate)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testing for COVID-19 (reverse-transcriptase PCR preferred)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testing for other respiratory viruses during respiratory virus season (PCR preferred, particularly for influenza)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rapid nasal PCR or culture for MRSA (if risk factors for MRSA, severe disease, or a biphasic illness [viral respiratory syndrome followed by deterioration])</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Screening test for HIV </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most hospitalized patients with severe CAP, including those admitted to the ICU, we obtain the tests bulleted above. In addition, we obtain bronchoscopic specimens for microbiologic testing when feasible, weighing the benefits of obtaining a microbiologic diagnosis against the risks of the procedure (eg, need for intubation, bleeding, bronchospasm, pneumothorax) on a case-by-case basis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In all cases, we modify this approach based on epidemiologic exposures, patient risk factors/clinical features, public health needs, and the likelihood that the test results would help refine the differential diagnosis and/or change management. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> − A substantial portion of patients initially diagnosed with CAP are ultimately found to have alternate diagnoses. Therefore, findings that further support or refute the initial diagnoses should continue to be sought as the patient’s course progresses  (<a class="graphic graphic_algorithm graphicRef131728" href="/d/graphic/131728.html" rel="external">algorithm 3</a>). The most common alternate diagnoses included heart failure, malignancy, pulmonary infarct, and fibrosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> − Most patients with CAP will show some signs of improvement within 48 to 72 hours of starting antibiotics. Failure to respond within this time period should raise suspicion for progression of infection with a drug resistant pathogen, development of complications (eg, lung abscess, empyema heart failure, other cardiac events), or an incorrect diagnosis. (See <a class="local">'Follow-up care'</a> above.)</p><p></p><p class="headingAnchor" id="H2518332049"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as author on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Claessens YE, Debray MP, Tubach F, et al. Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia. Am J Respir Crit Care Med 2015; 192:974.</a></li><li><a class="nounderline abstract_t">Weiss ZF, Cunha CB, Chambers AB, et al. Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11.</a></li><li><a class="nounderline abstract_t">Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501.</a></li><li><a class="nounderline abstract_t">Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278:1440.</a></li><li><a class="nounderline abstract_t">Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130:11.</a></li><li><a class="nounderline abstract_t">Takada T, Yamamoto Y, Terada K, et al. Diagnostic utility of appetite loss in addition to existing prediction models for community-acquired pneumonia in the elderly: a prospective diagnostic study in acute care hospitals in Japan. BMJ Open 2017; 7:e019155.</a></li><li><a class="nounderline abstract_t">Ebell MH, Chupp H, Cai X, et al. Accuracy of Signs and Symptoms for the Diagnosis of Community-acquired Pneumonia: A Meta-analysis. Acad Emerg Med 2020; 27:541.</a></li><li><a class="nounderline abstract_t">van Vugt SF, Verheij TJ, de Jong PA, et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J 2013; 42:1076.</a></li><li><a class="nounderline abstract_t">Teepe J, Broekhuizen BDL, Loens K, et al. Predicting the presence of bacterial pathogens in the airways of primary care patients with acute cough. CMAJ 2017; 189:E50.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53:503.</a></li><li><a class="nounderline abstract_t">Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 2014; 43:842.</a></li><li><a class="nounderline abstract_t">Flanders SA, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116:529.</a></li><li><a class="nounderline abstract_t">Holm A, Nexoe J, Bistrup LA, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57:547.</a></li><li><a class="nounderline abstract_t">Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125:1335.</a></li><li><a class="nounderline abstract_t">Ruiz-González A, Utrillo L, Bielsa S, et al. The Diagnostic Value of Serum C-Reactive Protein for Identifying Pneumonia in Hospitalized Patients with Acute Respiratory Symptoms. J Biomark 2016; 2016:2198745.</a></li><li><a class="nounderline abstract_t">van Vugt SF, Broekhuizen BD, Lammens C, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346:f2450.</a></li><li><a class="nounderline abstract_t">Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469.</a></li><li><a class="nounderline abstract_t">Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis 2017; 65:183.</a></li><li><a class="nounderline abstract_t">Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059.</a></li><li><a class="nounderline abstract_t">Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; :CD007498.</a></li><li><a class="nounderline abstract_t">Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 70:538.</a></li><li><a class="nounderline abstract_t">Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med 2018; 379:236.</a></li><li><a class="nounderline abstract_t">Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med 2018; 44:428.</a></li><li><a class="nounderline abstract_t">Jartti A, Rauvala E, Kauma H, et al. Chest imaging findings in hospitalized patients with H1N1 influenza. Acta Radiol 2011; 52:297.</a></li><li><a class="nounderline abstract_t">Hopstaken RM, Witbraad T, van Engelshoven JM, Dinant GJ. Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections. Clin Radiol 2004; 59:743.</a></li><li><a class="nounderline abstract_t">Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest 1996; 110:343.</a></li><li><a class="nounderline abstract_t">Makhnevich A, Sinvani L, Cohen SL, et al. The Clinical Utility of Chest Radiography for Identifying Pneumonia: Accounting for Diagnostic Uncertainty in Radiology Reports. AJR Am J Roentgenol 2019; 213:1207.</a></li><li><a class="nounderline abstract_t">Campbell SG, Murray DD, Hawass A, et al. Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia. Emerg Radiol 2005; 11:242.</a></li><li><a class="nounderline abstract_t">Atamna A, Shiber S, Yassin M, et al. The accuracy of a diagnosis of pneumonia in the emergency department. Int J Infect Dis 2019; 89:62.</a></li><li><a class="nounderline abstract_t">Loubet P, Tubiana S, Claessens YE, et al. Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication. Clin Microbiol Infect 2020; 26:382.e1.</a></li><li><a class="nounderline abstract_t">Feldman C. Pneumonia in the elderly. Clin Chest Med 1999; 20:563.</a></li><li><a class="nounderline abstract_t">Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117:305.</a></li><li><a class="nounderline abstract_t">Syrjälä H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27:358.</a></li><li><a class="nounderline abstract_t">Nyamande K, Lalloo UG, Vawda F. Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study. Br J Radiol 2007; 80:302.</a></li><li><a class="nounderline abstract_t">Wheeler JH, Fishman EK. Computed tomography in the management of chest infections: current status. Clin Infect Dis 1996; 23:232.</a></li><li><a class="nounderline abstract_t">Kunihiro Y, Tanaka N, Kawano R, et al. Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography. Eur Radiol 2019; 29:6089.</a></li><li><a class="nounderline abstract_t">Long L, Zhao HT, Zhang ZY, et al. Lung ultrasound for the diagnosis of pneumonia in adults: A meta-analysis. Medicine (Baltimore) 2017; 96:e5713.</a></li><li><a class="nounderline abstract_t">Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J. Accuracy of Lung Ultrasonography in the Diagnosis of Pneumonia in Adults: Systematic Review and Meta-Analysis. Chest 2017; 151:374.</a></li><li><a class="nounderline abstract_t">Staub LJ, Mazzali Biscaro RR, Kaszubowski E, Maurici R. Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis. J Emerg Med 2019; 56:53.</a></li><li><a class="nounderline abstract_t">Tsou PY, Chen KP, Wang YH, et al. Diagnostic Accuracy of Lung Ultrasound Performed by Novice Versus Advanced Sonographers for Pneumonia in Children: A Systematic Review and Meta-analysis. Acad Emerg Med 2019; 26:1074.</a></li><li><a class="nounderline abstract_t">Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.</a></li><li><a class="nounderline abstract_t">Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis. Clin Infect Dis 2017; 64:1328.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283:749.</a></li><li><a class="nounderline abstract_t">Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.</a></li><li><a class="nounderline abstract_t">File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.</a></li><li><a class="nounderline abstract_t">Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619.</a></li><li><a class="nounderline abstract_t">Ogawa H, Kitsios GD, Iwata M, Terasawa T. Sputum Gram Stain for Bacterial Pathogen Diagnosis in Community-acquired Pneumonia: A Systematic Review and Bayesian Meta-analysis of Diagnostic Accuracy and Yield. Clin Infect Dis 2020; 71:499.</a></li><li><a class="nounderline abstract_t">Asti L, Bartsch SM, Umscheid CA, et al. The potential economic value of sputum culture use in patients with community-acquired pneumonia and healthcare-associated pneumonia. Clin Microbiol Infect 2019; 25:1038.e1.</a></li><li><a class="nounderline abstract_t">Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 Suppl 4:S296.</a></li><li><a class="nounderline abstract_t">van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:672.</a></li><li class="breakAll">Gilbert D, Spellberg, Bartlett JG. Recommendations for diagnostic studies in respiratory tract infections (Position paper of the Infectious Diseases Society of America). Clin Infect Dis 2010.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Severe coinfection with seasonal influenza A (H3N2) virus and Staphylococcus aureus--Maryland, February-March 2012. MMWR Morb Mortal Wkly Rep 2012; 61:289.</a></li><li><a class="nounderline abstract_t">Landry ML. Diagnostic tests for influenza infection. Curr Opin Pediatr 2011; 23:91.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Evaluation of 11 commercially available rapid influenza diagnostic tests--United States, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:873.</a></li><li><a class="nounderline abstract_t">Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52:432.</a></li><li><a class="nounderline abstract_t">Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis 2013; 57:e22.</a></li><li><a class="nounderline abstract_t">Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.</a></li><li><a class="nounderline abstract_t">Karwa M, Currie B, Kvetan V. Bioterrorism: Preparing for the impossible or the improbable. Crit Care Med 2005; 33:S75.</a></li><li><a class="nounderline abstract_t">Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144.</a></li><li><a class="nounderline abstract_t">Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis 2008; 46:183.</a></li><li><a class="nounderline abstract_t">Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.</a></li><li><a class="nounderline abstract_t">van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24:241.</a></li><li><a class="nounderline abstract_t">Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95:78.</a></li><li><a class="nounderline abstract_t">Chalasani NP, Valdecanas MA, Gopal AK, et al. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995; 108:932.</a></li><li><a class="nounderline abstract_t">Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009; 49:409.</a></li><li><a class="nounderline abstract_t">Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123:1142.</a></li><li><a class="nounderline abstract_t">Corbo J, Friedman B, Bijur P, Gallagher EJ. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004; 21:446.</a></li><li><a class="nounderline abstract_t">Campbell SG, Marrie TJ, Anstey R, et al. Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med J 2003; 20:521.</a></li><li><a class="nounderline abstract_t">Haessler S, Lindenauer PK, Zilberberg MD, et al. Blood Cultures Versus Respiratory Cultures: 2 Different Views of Pneumonia. Clin Infect Dis 2020; 71:1604.</a></li><li><a class="nounderline abstract_t">Benenson RS, Kepner AM, Pyle DN 2nd, Cavanaugh S. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007; 33:1.</a></li><li><a class="nounderline abstract_t">Jefferson H, Dalton HP, Escobar MR, Allison MJ. Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975; 64:689.</a></li><li><a class="nounderline abstract_t">Harris AM, Bramley AM, Jain S, et al. Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infect Dis 2017; 4:ofx014.</a></li><li><a class="nounderline abstract_t">Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25:758.</a></li><li><a class="nounderline abstract_t">Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121:1486.</a></li><li><a class="nounderline abstract_t">Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39:165.</a></li><li><a class="nounderline abstract_t">Busk MF, Rosenow EC 3rd, Wilson WR. Invasive procedures in the diagnosis of pneumonia. Semin Respir Infect 1988; 3:113.</a></li><li><a class="nounderline abstract_t">Cordero E, Pachón J, Rivero A, et al. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21:362.</a></li><li><a class="nounderline abstract_t">Reed WW, Byrd GS, Gates RH Jr, et al. Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med 1996; 165:197.</a></li><li><a class="nounderline abstract_t">Boonyaratanakornkit J, Vivek M, Xie H, et al. Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. J Infect Dis 2020; 221:379.</a></li><li><a class="nounderline abstract_t">van Someren Gréve F, Juffermans NP, Bos LDJ, et al. Respiratory Viruses in Invasively Ventilated Critically Ill Patients-A Prospective Multicenter Observational Study. Crit Care Med 2018; 46:29.</a></li><li><a class="nounderline abstract_t">Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med 2017; 5:401.</a></li><li><a class="nounderline abstract_t">Saarela E, Tapiainen T, Kauppila J, et al. Impact of multiplex respiratory virus testing on antimicrobial consumption in adults in acute care: a randomized clinical trial. Clin Microbiol Infect 2020; 26:506.</a></li><li><a class="nounderline abstract_t">Evans SE, Jennerich AL, Azar MM, et al. Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2021; 203:1070.</a></li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Wu X, Wang Q, Wang M, et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. Respiration 2015; 89:343.</a></li><li><a class="nounderline abstract_t">Hanson KE, Azar MM, Banerjee R, et al. Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA's Diagnostics Committee. Clin Infect Dis 2020; 71:2744.</a></li><li><a class="nounderline abstract_t">Mitton B, Rule R, Said M. Laboratory evaluation of the BioFire FilmArray Pneumonia plus panel compared to conventional methods for the identification of bacteria in lower respiratory tract specimens: a prospective cross-sectional study from South Africa. Diagn Microbiol Infect Dis 2021; 99:115236.</a></li><li><a class="nounderline abstract_t">Buchan BW, Windham S, Balada-Llasat JM, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections. Infect Dis (Lond) 2020; 52:479.</a></li><li><a class="nounderline abstract_t">Prendki V, Huttner B, Marti C, et al. Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients: a prospective cohort study. Clin Microbiol Infect 2019; 25:1114.</a></li><li><a class="nounderline abstract_t">Webber DM, Wallace MA, Burnham CA, Anderson NW. Evaluation of the BioFire FilmArray Pneumonia Panel for Detection of Viral and Bacterial Pathogens in Lower Respiratory Tract Specimens in the Setting of a Tertiary Care Academic Medical Center. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Gilbert DN, Leggett JE, Wang L, et al. Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel. Diagn Microbiol Infect Dis 2021; 99:115246.</a></li><li><a class="nounderline abstract_t">Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007; 45:983.</a></li><li><a class="nounderline abstract_t">Tang KL, Eurich DT, Minhas-Sandhu JK, et al. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med 2011; 171:1193.</a></li><li><a class="nounderline abstract_t">Macdonald C, Jayathissa S, Leadbetter M. Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice. Intern Med J 2015; 45:329.</a></li><li><a class="nounderline abstract_t">Little BP, Gilman MD, Humphrey KL, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. AJR Am J Roentgenol 2014; 202:54.</a></li><li><a class="nounderline abstract_t">Mortensen EM, Copeland LA, Pugh MJ, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med 2010; 123:66.</a></li></ol></div><div id="topicVersionRevision">Topic 7032 Version 77.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31413077" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23523447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038304" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356004" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167296" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840376" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122806" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnostic utility of appetite loss in addition to existing prediction models for community-acquired pneumonia in the elderly: a prospective diagnostic study in acute care hospitals in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32329557" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Accuracy of Signs and Symptoms for the Diagnosis of Community-acquired Pneumonia: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349450" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27777252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predicting the presence of bacterial pathogens in the airways of primary care patients with acute cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865188" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114960" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063814" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17727747" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078743" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27610265" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Diagnostic Value of Serum C-Reactive Protein for Identifying Pneumonia in Hospitalized Patients with Acute Respiratory Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633005" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477418" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407054" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738090" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972110" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31241140" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781385" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663044" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498366" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chest imaging findings in hospitalized patients with H1N1 influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262550" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509449" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Clinical Utility of Chest Radiography for Identifying Pneumonia: Accounting for Diagnostic Uncertainty in Radiology Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133615" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479761" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The accuracy of a diagnosis of pneumonia in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31284034" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516904" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pneumonia in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15336579" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709887" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High-resolution computed tomography for the diagnosis of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005518" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Computed tomography in the management of chest infections: current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062135" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099332" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lung ultrasound for the diagnosis of pneumonia in adults: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27818332" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Accuracy of Lung Ultrasonography in the Diagnosis of Pneumonia in Adults: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30314929" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211896" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnostic Accuracy of Lung Ultrasound Performed by Novice Versus Advanced Sonographers for Pneumonia in Children: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640810" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199524" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10683053" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278083" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14683661" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25337751" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504334" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sputum Gram Stain for Bacterial Pathogen Diagnosis in Community-acquired Pneumonia: A Systematic Review and Bayesian Meta-analysis of Diagnostic Accuracy and Yield.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590113" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The potential economic value of sputum culture use in patients with community-acquired pneumonia and healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460288" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnostic tests for agents of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061709" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061709" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534762" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe coinfection with seasonal influenza A (H3N2) virus and Staphylococcus aureus--Maryland, February-March 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150446" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Diagnostic tests for influenza infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114254" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of 11 commercially available rapid influenza diagnostic tests--United States, 2011-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248682" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248368" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845951" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640684" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bioterrorism: Preparing for the impossible or the improbable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752529" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18272956" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171248" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19947881" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902529" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207022" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555163" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19555286" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684305" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208227" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Limited usefulness of initial blood cultures in community acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623837" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31665249" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Blood Cultures Versus Respiratory Cultures: 2 Different Views of Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630066" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Selective use of blood cultures in emergency department pneumonia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1190128" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Transportation delay and the microbiological quality of clinical specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480285" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2438299" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Nonvalue of sputum culture in the management of lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006433" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307023" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3041512" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Invasive procedures in the diagnosis of pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072920" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8987424" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31541573" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991822" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Respiratory Viruses in Invasively Ventilated Critically Ill Patients-A Prospective Multicenter Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28392237" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31574339" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of multiplex respiratory virus testing on antimicrobial consumption in adults in acute care: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929301" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791384" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32369578" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA's Diagnostics Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33130507" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Laboratory evaluation of the BioFire FilmArray Pneumonia plus panel compared to conventional methods for the identification of bacteria in lower respiratory tract specimens: a prospective cross-sectional study from South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350045" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32319831" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30641227" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32321782" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Evaluation of the BioFire FilmArray Pneumonia Panel for Detection of Viral and Bacterial Pathogens in Lower Respiratory Tract Specimens in the Setting of a Tertiary Care Academic Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33253962" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire®Pneumonia FilmArray®Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879912" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518934" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583286" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24370128" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102994" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Diagnosis of pulmonary malignancy after hospitalization for pneumonia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
